Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Stock Information for Processa Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.